- Sep 19 2016
Dr. Bedu-Addo to Chair the Therapeutics/Cancer Immunotherapies Session and Present Phase I/IIA Results
Dr. Bedu-Addo to Chair the Therapeutics/Cancer Immunotherapies Session and Present Phase I/IIA Results from the PDS0101 Program at the World Vaccine Congress on Oct 10, 2016
September 19, 2016—PDS Biotechnology announced today that Dr. Frank Bedu-Addo, President and CEO, will Chair the Therapeutics session at the World Vaccine Congress, Europe on October 10. The Conference will be held this year in Barcelona from October 10 – 12. Dr. Bedu-Addo will also present data from the company’s recently completed Phase I/IIA clinical trial with PDS’s lead cancer immunotherapy, PDS0101, being developed to treat HPV-induced cancers, including Cervical, Anal, and Head and Neck cancers.